RZLT
Rezolute Inc
NASDAQ: RZLT · HEALTHCARE · BIOTECHNOLOGY
$4.22
+2.68% today
Updated 2026-10-28
Market cap
$369.48M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.75
Dividend yield
—
52W range
$1 – $11
Volume
1.6M
Rezolute Inc (RZLT) Insider transactions
Net insider activity
Net buying (5,378,639 shares)
Buy transactions
91
Sell transactions
7
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-10-21 | EVANS, DARON | CFO | G | 16,000 | — | — |
| 2026-10-21 | EVANS, DARON | CFO | G | 4,000 | — | — |
| 2026-09-02 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Sale | 2,267 | $4.50 | $10201.50 |
| 2026-07-02 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Sale | 3,062 | $4.99 | $15279.38 |
| 2026-07-02 | EVANS, DARON | CFO | Sale | 3,062 | $4.99 | $15279.38 |
| 2026-07-02 | ELAM, NEVAN C | Director, CEO | Sale | 8,004 | $4.99 | $39939.96 |
| 2026-03-30 | EVANS, DARON | CFO | Buy | 10,000 | $2.85 | $28500.00 |
| 2026-03-02 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Sale | 11,439 | $2.99 | $34202.61 |
| 2026-03-02 | EVANS, DARON | CFO | Sale | 11,438 | $2.99 | $34199.62 |
| 2026-03-02 | ELAM, NEVAN C | Director, CEO | Sale | 27,618 | $2.99 | $82577.82 |
| 2025-12-16 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 28,000 | $1.70 | $47600.00 |
| 2025-12-16 | HOGENHUIS, WLADIMIR | Director | Buy | 5,650 | $1.69 | $9548.50 |
| 2025-12-15 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Buy | 12,000 | $1.62 | $19438.80 |
| 2025-12-15 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Buy | 100 | $1.60 | $160.00 |
| 2025-12-15 | EVANS, DARON | CFO | Buy | 40,000 | $1.77 | $70640.00 |
| 2025-12-15 | EVANS, DARON | CFO | Buy | 2,500 | $1.79 | $4462.50 |
| 2025-12-15 | ELAM, NEVAN C | Director, CEO | Buy | 32,000 | $1.59 | $50880.00 |
| 2025-12-09 | EVANS, DARON | CFO | Buy | 10,549 | $5.04 | $53166.96 |
| 2025-11-19 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 72,000 | — | — |
| 2025-11-19 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 123,000 | — | — |
| 2025-11-19 | LABRUCHERIE, GIL M | Director | Buy | 12,000 | — | — |
| 2025-11-19 | LABRUCHERIE, GIL M | Director | Buy | 21,000 | — | — |
| 2025-11-19 | KREHER, NERISSA | Director | Buy | 12,000 | — | — |
| 2025-11-19 | KREHER, NERISSA | Director | Buy | 21,000 | — | — |
| 2025-11-19 | KIM, YOUNG-JIN | Director | Buy | 12,000 | — | — |
| 2025-11-19 | KIM, YOUNG-JIN | Director | Buy | 21,000 | — | — |
| 2025-11-19 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Buy | 19,000 | — | — |
| 2025-11-19 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Buy | 32,000 | — | — |
| 2025-11-19 | HOGENHUIS, WLADIMIR | Director | Buy | 12,000 | — | — |
| 2025-11-19 | HOGENHUIS, WLADIMIR | Director | Buy | 21,000 | — | — |
| 2025-11-19 | HARRIS, ERIK | Director | Buy | 12,000 | — | — |
| 2025-11-19 | HARRIS, ERIK | Director | Buy | 21,000 | — | — |
| 2025-11-19 | FAUCHET, PHILIPPE | Director | Buy | 12,000 | — | — |
| 2025-11-19 | FAUCHET, PHILIPPE | Director | Buy | 21,000 | — | — |
| 2025-11-19 | EVANS, DARON | CFO | Buy | 63,000 | — | — |
| 2025-11-19 | EVANS, DARON | CFO | Buy | 107,000 | — | — |
| 2025-11-19 | ELAM, NEVAN C | Director, CEO | Buy | 186,000 | — | — |
| 2025-11-19 | ELAM, NEVAN C | Director, CEO | Buy | 317,000 | — | — |
| 2025-08-18 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Buy | 275,000 | — | — |
| 2025-08-18 | KARNAWAT, SUNIL RATILAL | Chief Commercial Officer | Buy | 25,000 | — | — |
| 2025-06-25 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 2,500 | $4.38 | $10939.00 |
| 2025-06-24 | EVANS, DARON | CFO | Buy | 5,000 | $4.05 | $20250.00 |
| 2025-06-13 | KREHER, NERISSA | Director | Buy | 3,076 | $3.25 | $9997.00 |
| 2025-06-13 | KIM, YOUNG-JIN | Director | Buy | 1,230,769 | $3.25 | $4.00M |
| 2025-06-10 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 15,000 | — | — |
| 2025-06-10 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 26,000 | — | — |
| 2025-06-10 | LABRUCHERIE, GIL M | Director | Buy | 5,000 | — | — |
| 2025-06-10 | LABRUCHERIE, GIL M | Director | Buy | 9,000 | — | — |
| 2025-06-10 | KREHER, NERISSA | Director | Buy | 5,000 | — | — |
| 2025-06-10 | KREHER, NERISSA | Director | Buy | 9,000 | — | — |
| 2025-06-10 | KIM, YOUNG-JIN | Director | Buy | 5,000 | — | — |
| 2025-06-10 | KIM, YOUNG-JIN | Director | Buy | 9,000 | — | — |
| 2025-06-10 | HOGENHUIS, WLADIMIR | Director | Buy | 5,000 | — | — |
| 2025-06-10 | HOGENHUIS, WLADIMIR | Director | Buy | 9,000 | — | — |
| 2025-06-10 | FAUCHET, PHILIPPE | Director | Buy | 5,000 | — | — |
| 2025-06-10 | FAUCHET, PHILIPPE | Director | Buy | 9,000 | — | — |
| 2025-06-10 | EVANS, DARON | CFO | Buy | 15,000 | — | — |
| 2025-06-10 | EVANS, DARON | CFO | Buy | 26,000 | — | — |
| 2025-06-10 | ELAM, NEVAN C | Director, CEO | Buy | 40,000 | — | — |
| 2025-06-10 | ELAM, NEVAN C | Director, CEO | Buy | 68,000 | — | — |
| 2025-03-31 | HOGENHUIS, WLADIMIR | Director | Buy | 6,758 | $2.92 | $19733.36 |
| 2025-03-27 | ELAM, NEVAN C | Director, CEO | Buy | 12,302 | $2.85 | $34999.19 |
| 2025-03-26 | EVANS, DARON | CFO | Buy | 10,000 | $2.89 | $28900.00 |
| 2025-03-25 | HARRIS, ERIK | Director | Buy | 60,000 | — | — |
| 2025-02-18 | HOGENHUIS, WLADIMIR | Director | Buy | 10,000 | $4.70 | $47000.00 |
| 2025-02-16 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 45,000 | — | — |
| 2025-02-16 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 77,000 | — | — |
| 2025-02-16 | LABRUCHERIE, GIL M | Director | Buy | 15,000 | — | — |
| 2025-02-16 | LABRUCHERIE, GIL M | Director | Buy | 25,500 | — | — |
| 2025-02-16 | KREHER, NERISSA | Director | Buy | 15,000 | — | — |
| 2025-02-16 | KREHER, NERISSA | Director | Buy | 25,500 | — | — |
| 2025-02-16 | KIM, YOUNG-JIN | Director | Buy | 15,000 | — | — |
| 2025-02-16 | KIM, YOUNG-JIN | Director | Buy | 25,500 | — | — |
| 2025-02-16 | HOGENHUIS, WLADIMIR | Director | Buy | 15,000 | — | — |
| 2025-02-16 | HOGENHUIS, WLADIMIR | Director | Buy | 25,500 | — | — |
| 2025-02-16 | FAUCHET, PHILIPPE | Director | Buy | 15,000 | — | — |
| 2025-02-16 | FAUCHET, PHILIPPE | Director | Buy | 25,500 | — | — |
| 2025-02-16 | EVANS, DARON | CFO | Buy | 45,000 | — | — |
| 2025-02-16 | EVANS, DARON | CFO | Buy | 77,000 | — | — |
| 2025-02-16 | ELAM, NEVAN C | Director, CEO | Buy | 120,000 | — | — |
| 2025-02-16 | ELAM, NEVAN C | Director, CEO | Buy | 204,000 | — | — |
| 2024-12-18 | EVANS, DARON | CFO | Buy | 10,000 | $4.29 | $42900.00 |
| 2024-12-12 | EVANS, DARON | CFO | Buy | 9,000 | $4.60 | $41400.00 |
| 2024-09-24 | HOGENHUIS, WLADIMIR | Director | Buy | 4,259 | $4.70 | $20017.30 |
| 2024-09-23 | EVANS, DARON | CFO | Buy | 100,000 | — | — |
| 2024-06-25 | KIM, YOUNG-JIN | Director | Buy | 1,250,000 | $4.00 | $5.00M |
| 2024-06-25 | HOGENHUIS, WLADIMIR | Director | Buy | 4,815 | $4.15 | $19982.25 |
| 2024-06-14 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 4,000 | $3.91 | $15639.60 |
| 2024-06-14 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 3,000 | $3.91 | $11724.60 |
| 2024-06-14 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 300 | $3.96 | $1188.00 |
| 2024-06-14 | EVANS, DARON | CFO | Buy | 40,000 | $4.04 | $161568.00 |
| 2024-05-29 | EVANS, DARON | CFO | Buy | 451 | $3.50 | $1578.50 |
| 2024-05-24 | EVANS, DARON | CFO | Buy | 2,942 | $3.23 | $9502.66 |
| 2024-05-23 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 6,000 | $2.68 | $16057.80 |
| 2024-05-23 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 1,500 | $2.72 | $4080.00 |
| 2024-05-23 | EVANS, DARON | CFO | Buy | 58 | $2.85 | $165.30 |
| 2024-03-28 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 500 | $2.55 | $1275.00 |
| 2024-03-15 | EVANS, DARON | CFO | Buy | 20,000 | $1.69 | $33830.00 |
| 2024-03-14 | ROBERTS, BRIAN KENNETH | Chief Medical Officer | Buy | 10,000 | $1.88 | $18800.00 |
| 2024-03-08 | EVANS, DARON | CFO | Buy | 50,000 | $1.93 | $96345.00 |
Frequently asked questions
Are RZLT insiders buying or selling?
Over the transactions on record, RZLT insiders have been net buyers, with about $231680.27 in stock sold across 7 sales, against 35 open-market purchases.
Does insider selling at RZLT mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which RZLT insiders are selling the most?
Recent selling is concentrated in a few names. ELAM, NEVAN C accounts for the largest share on record, with about $122517.78 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.